IPO
IPO
Best Performers
Forthcoming Issues
Closed Issues
New Listings
Current Issues
IPO Performance
IPO News
IPO Analysis
Basis of Allotment
Draft Prospectus
  HOME  >  IPO  >   IPO SNAPSHOT
IPO Snapshot    
Gland Pharma Ltd.
Issue Open Date 09-Nov-20  
Issue Closing Date 11-Nov-20  
Application Money 100  
Allotment Money  
Price Band 1490 - 1500  
Minimium Application No. 10  
Issue Size (Shares) 30237879  
Market Lot 1.00  
Objective
To finance the incremental working capital requirements of our CompanyTo meet funding requirements for capital expenditure requirementsTo meet the general corporate purposes
Category No. of Shares No. of Shares Subscription Ratio
  Offered / Reserved Bid For  
Non-Institutional Investors   6479546   3294470   0.51  
Qualified Institutional Buyers   8639394   55250350   6.40  
Retail Individual Investors   15118939   3610850   0.24  
Business Description
Promoter's Holding
Total Share Capital   114662620  
Offered to Public   43196968  
Promoter's Holding (Pre-Issue)   74  
Promoter's Holding (Post-Issue)   70.22  
Address
Survey No. 143-148
150 & 151
Near Gandimaisamma 'x' Roads
D. P. Pally
Dundigal Gandimaisamma Mandal
Medchal- Malkajgiri District
Hyderabad ,
Telangana ,
500043
Phone: 040 30510999
Email: gland@glandpharma.com / investor@glandpharma.com
Website: www.glandpharma.com
Registrar
Link Intime India Pvt Ltd.
C 101
247 Park
LBS Marg
Vikhroli (West)
Mumbai
Listed at
BSE, NSE
Lead Manager
Citigroup Global Markets India Pvt Ltd.
Haitong Securities India Pvt Ltd.
Kotak Mahindra Capital Co Ltd
Nomura Financial Advisory & Securities (India) Pvt Ltd.
Promoters
Fosun Pharma Industrial Pte. Ltd.
Shanghai Fosun Pharmaceutical (Group) Co. Ltd.
Back Back TopTop
Disclaimer | Privacy Policy | Grievance | FAQ | Sitemap | Client Registration | Useful Links| Anti Money Laundering | Inactive Client Policy | Scores
Vernacular Kyc | Advisory For Investors | Investor Adviser | Filing complaints on SCORES - Easy & quick
Publishing of investor charter information | Annexure A – Investor charter of brokers |
Annexure A – Investor charter of DP | Annexure B –Linked content for information to charter for DP | Annexure B & C (investor complaint data) broker & DP
Investor Awareness & Information | Advisory-KYC Compliance | E-Voting NSE | E-Voting BSE | Details of Client Bank Accounts | Risk Disclosure | NSE FO Risk disclosure
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source: Click Here.